-
Results reveal that opioids are increasingly popular in treating pain connected with rheumatic and musculoskeletal diseases. Experts indicate that measures need to be taken to ensure a safe and sensible use of these analgesics.
-
Current data suggest patients with inflammatory rheumatic conditions do not exhibit an increased frequency of COVID-19 infection or a more severe course of disease. Risk factors such as older age, obesity, etc, seem more important.
-
Results were presented of a phase 2 trial for MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a in von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC).
-
E2108 trial results showed that local therapy did not improve overall survival (OS) when compared with optimal systemic therapy alone. Added locoregional therapy also failed to improve 3-year progression-free survival (PFS).
-
Tiragolumab and atezolizumab showed improved objective response rate over tiragolumab and placebo in chemotherapy-naïve locally advanced or metastatic non-small cell lung cancer (NSCLC).
-
Addition of tremelimumab to frontline durvalumab and platinum-based chemotherapy did not demonstrate a significant improvement in overall survival in patients with extensive-stage small-cell lung cancer, missing the co-primary endpoint of the phase 3 CASPIAN study.
-
An initial report of patients with heavily pre-treated metastatic HER2-expressing colorectal cancer shows particularly efficacy with trastuzumab deruxtecan in patients with high HER2-positivity.
-
In-depth tumor molecular characterization of children and adolescents who have relapsed after initial therapy, and for whom there are no established treatment concepts available, can offer diagnostic insight and potential novel therapeutic approaches.
-
The phase 3 KEYNOTE-604 trial showed that patients with extensive-stage small-cell lung cancer who received pembrolizumab with etoposide/platinum, compared with patients who received EP and placebo, did not benefit from improved overall survival.
-
A retrospective cohort study of patients presenting with cardiotoxicity after treatment with fluoropyrimidines suggests that switching to S-1 (i.e. a combination of tegafur, gimeracil, and oteracil, at a molar ratio of 1:0.4:1) is safe for these patients and supports treatment continuation.
-
The final overall survival (OS) results for 3 major trials in non-metastatic castration-resistant prostate cancer (nmCRPC) were presented: the ARAMIS (darolutamide versus placebo), SPARTAN (apalutamide versus placebo) and PROSPER (enzalutamide versus placebo) trials.
-
The first phase 3 study of pembrolizumab versus standard-of-care demonstrated superiority for first-line pembrolizumab in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.
-
Older age, poor performance status, and progressing cancer were strongly associated with increased mortality, especially within patient subsets admitted to the ICU and/or that required intubation.
-
In a global registry, 428 thoracic cancer patients infected with COVID-19 have been followed up, and the data are concerning. 169 have recovered, 119 have ongoing COVID-19 infection, but 141 have died.
-
At a 3-years median follow-up, the randomized, phase 3 EORTC 1325/KEYNOTE-054 trial demonstrated that adjuvant pembrolizumab taken for up to 1 year in high-risk stage III melanoma patients improved recurrence-free survival (RFS), with a consistent effect across subgroups.
-
The phase 3 JAVELIN Bladder 100 study showed at its primary endpoint significantly longer overall survival with avelumab first-line maintenance versus control, both in the overall population and the PD-L1+ population, for patients with locally advanced or metastatic urothelial cancer.
-
In patients with platinum-sensitive relapsed ovarian cancer harboring BRCA1/2 mutation, final overall survival (OS) results from the phase 3 SOLO2/ENGOT-ov21 trial showed significant benefit for patients receiving maintenance treatment with olaparib over placebo.
-
Osimertinib demonstrated a significant benefit for patients with stage IB, II, or IIIA EGFR-mutant non-small cell lung cancer with complete tumor resection in the phase 3 ADAURA trial.
-
In patients with newly diagnosed multiple myeloma, carfilzomib with lenalidomide and dexamethasone (KRd) did not improve progression-free survival (PFS), when compared with the current standard of care of bortezomib with lenalidomide and dexamethasone (VRd).
-
Bladder cancer is the sixth most common tumor diagnosis in the EU and up to 70% of tumors develop recurrences within a year. Early detection is a major problem. A new urine test could improve screening.
